Dr. Scott Liu, one of the global partners of Fosun International Limited, the Co-founder, President and CEO at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to setting up Henlius in 2010, he has previously had postdoctoral training in Biology at Stanford University and has served several executive positions at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb Technical Operations, and the Director of QAL (QC) at Amgen Inc. Fremont (now Boehringer Ingelheim Fremont Inc.). Dr. Liu was the recipient of the Bristol-Myers Squibb“Technical Operations Presidential Award”in 2004. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of Technical Guidelines of Biosimilar Development and Evaluation to promote the innovation and globalization of the biopharmaceutical industry in China. He received his Ph.D. degree in Biology from the Purdue University.

Dr. Wei-Dong Jiang, the co-founder and Chief Scientific Officer at Shanghai Henlius Biotech Inc., graduated from Hangzhou University with a bachelor degree of biology, and Chinese Academy of Sciences with a master degree of cell biology. He later continued his Ph.D. study in Microbiology and Molecular Biology in the University of Giessen in Germany. After that, he did his post-doctoral research at University of California. Following his academic career, he developed his expertise in biopharmaceutical R&D and production, including drug discovery, antibody/protein engineering, production cell line development, process optimization, and regulatory filing, by serving as a senior scientist and/or director for companies such as Vasgene Therapeutics Inc. and Applied Molecular Evolution Inc.

Mr. Wenjie Zhang is Senior Vice President, Chief Commercial Operation Officer and Chief Strategy Officer of Henlius.
Wenjie has 25 years of commercial experience in the pharmaceutical industry. Before joining Henlius in March 2019, Wenjie was the General Manager of Amgen China where he was leading company’s overall efforts in expanding business into Chinese market and help Chinese patients to access Amgen’s innovative medicines. Under Wenjie’s leadership, Amgen built its commercial infrastructure, organization, and competency. Wenjie successfully launched Repatha® (evolocumab), Amgen’s first product in China. Wenjie joined Amgen in 2014 as Executive Director, Marketing for Japan and Asia Pacific region.
Prior to Amgen, he worked as vice president, Oncology for Roche in Shanghai, China, where he was managing a significant P&L and 850 staff in the oncology franchise marketing business unit. Wenjie successfully grew the Roche oncology portfolio including Avastin® (bevacizumab), Tarceva® (erlotinib) and MABTHERA® (rituximab) in the China market. Wenjie also led Roche China oncology franchise in pipeline planning, franchise strategy, and franchise marketing.
Before then, he served as the head of Business Development at Bayer Schering Pharma, Asia Pacific Headquarters, Product Manager of US Marketing, Business Development Manager and Deputy Director of Global Marketing at Bayer Pharmaceuticals USA. In this role, he led the fastest growing business unit within Bayer China. Wenjie also had dual responsibility as Head of the same business unit for Asia Pacific region. He successfully launched multiple products in China including Nexavar, Kogenate and Betaferon.
Wenjie obtained his MBA from the Yale University School of Management in 1998. He graduated with a B.S. in microbiology from Shandong University in Jinan, China in 1990.

Mr. James Guo, Senior Vice President and Secretary of the Board, graduated from Genetics and Genetic Engineering Department of Fudan University, and holds a MBA degree from Zhejiang University. He has previously served as research manager, vice president and chief engineer in Hangzhou Jiuyuan Gene Engineering Co., Ltd., Hangzhou Taishi Biotechnology Co., Ltd., Zhejiang Cifu Pharmaceutical Co. and Shanghai Chemo Wanbang Biopharma Co., Ltd. Mr. James Guo is experienced in biopharmaceutical development and production, and familiar with all types of national laws and regulations. He has been involved in the development of a Category II new drug which is the first listed recombinant human granulocyte colony-stimulating factor (rhG-CSF) injection in China. He was awarded Outstanding Technology Development Talent of Hangzhou, Second Prize for Science and Technology Progress Award of Zhejiang Province and First Prize for Science and Technology Progress Award of Hangzhou. In addition, Mr. James Guo is the vice-chairman of Shanghai Biopharmaceutics Industry Association Monoclonal Antibody Drug Professional Committee currently.

 Alvin Luk, joined Henlius in 2017 as Senior Vice President and Chief Medical Officer. Dr. Luk has been in the biotechnology and pharmaceutical industries for approximately 20 years. Prior to joining the Group, he has held executive roles at companies such as Spark Therapeutics, Inc.,Biogen-Hemophilia (acquired by Sanofi in 2018), Bayer Schering Pharma LLC., Avigen, Inc.(acquired by Genzyme Corporation in 2005) and Tularik, Inc. (acquired by Amgen Inc. in 2003) since 1998. Until 2003, his early researches were primarily investigating gene regulation and expression with the emphasis on rare diseases, oncological diseases, biologics and regenerative medicines. He served on the Clinical Design Committee for rare disease at the U.S. Food and Drug Administration focusing on adaptive clinical trial design to shorten drug development timeline between 2006 and 2009. Under his leadership in strategic drug development, he has won regulatory marketing approvals of 16 products in neurology, ophthalmology, gene/cell therapy, hematology and cancer therapy as of today. Dr. Luk has published over 60 book chapters, scientific and medical articles in highly regarded peer-reviewed journals, including New England Journal of Medicine, Nature, Cell, and Science, and is an inventor on over 9 patent applications. Dr. Luk holds an MBA from Harvard Business School in January 2012, earned his doctoral degree in neuroscience from the University of California San Francisco and Bachelor’s degree in Molecular and Cell Biology from the University of California Berkeley in the United States.

Ms. Cecie Jiang, Senior Vice President of Quality, received her Bachelor degree in Applied Chemistry from China Agricultural University and Master degree in Microbiology from the University of Wisconsin – Madison. She has previously served the Vice President of Global Quality and Compliance for TWi Pharmaceuticals, Director of Quality for several companies including Boehringer Ingelheim, Stryker, Aphena Pharma Solutions. She also worked at Novartis, Perrigo and Bristol-Myers Squibb as QO Project Manager and QC Sr. Supervisor. Cecie has over 20 years of leadership experience in the pharmaceutical, medical device, and biotech industries with strong knowledge in quality system management, manufacturing transfers, QC Laboratories, and validations. She has led multiple successful global regulatory inspections and ISO audits for different companies.

Mr. Xin Zhang, Vice President of Global Clinical and Medical Affairs, holds a M.D. degree from Normal Bethune University of Medical Sciences and Master Degree from University of Texas Health Science Center of Houston, Graduate school of Biomedical Sciences. Mr. Xin Zhang has over 20 years of experience in drug development of pharmaceutical industry, holding important positions in Merck, Bayer Healthcare LLC and Biogen Idec.

Dr. Zidong Zhang, Chief Financial Officer, graduated from Fudan University for BS in chemistry, then obtained Ph.D. degree from Boston University in Biochemistry and MBA from Duke University the Fuqua School of Business. Dr. Zhang had worked as Equity Analyst for UBS in New York, covering US large Cap Pharmaceuticals and Specialty Pharmaceutical sector. He has previously worked as an equity analyst for UBS in New York, covering US large cap pharmaceuticals and specialty pharmaceutical sector  with a key focus in therapeutic areas as Oncology(especially for Immuno Oncology), autoimmune diseases, and other areas. He was an internal consultant for Bayer AG, a global pharmaceutical company, where he had multiple projects across the United States, Europe and China, including strategic planning and market forecasts for United States and China, merger and acquisition, organisational structure design and implementation.

Ms. Ping Cao, Vice President of Business Development, graduated from Tianjin University with a BS in Material Science & Engineering and MS in Chemical Engineering and also obtained her MS in Organic Chemistry at Michigan State University. She previously worked at Tyger Scientific, Ferro,Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ms. Ping Cao increased the business revenue 600% in 4 years. At BMS, she was responsible for global business development at CMO (contract manufacture operation) and accomplished significant sales growth. Then Ms. Cao joined business development team focusing on technology transactions. She negotiated and executed 36 technology collaboration deals to expedite the company’s drug discovery and development process. As a reward for her accomplishment, Ms. Cao received the Distinguished Employee Award, Innovation Award, and etc. at BMS. At Abzena, she developed and executed the business strategy of offering integrated contract manufacture service of biologics and antibody drug conjugates based on company core technologies of antibody drug conjugation and humanization, which greatly enhanced the company’s business growth worldwide.